169 related articles for article (PubMed ID: 19601747)
1. Advances in development of inhibitors of 17beta hydroxysteroid dehydrogenases.
Poirier D
Anticancer Agents Med Chem; 2009 Jul; 9(6):642-60. PubMed ID: 19601747
[TBL] [Abstract][Full Text] [Related]
2. Inhibitors of 17 beta-hydroxysteroid dehydrogenases.
Poirier D
Curr Med Chem; 2003 Mar; 10(6):453-77. PubMed ID: 12570693
[TBL] [Abstract][Full Text] [Related]
3. Contribution to the development of inhibitors of 17β-hydroxysteroid dehydrogenase types 1 and 7: key tools for studying and treating estrogen-dependent diseases.
Poirier D
J Steroid Biochem Mol Biol; 2011 May; 125(1-2):83-94. PubMed ID: 21182944
[TBL] [Abstract][Full Text] [Related]
4. 17β-Hydroxysteroid dehydrogenases (17β-HSDs) as therapeutic targets: protein structures, functions, and recent progress in inhibitor development.
Marchais-Oberwinkler S; Henn C; Möller G; Klein T; Negri M; Oster A; Spadaro A; Werth R; Wetzel M; Xu K; Frotscher M; Hartmann RW; Adamski J
J Steroid Biochem Mol Biol; 2011 May; 125(1-2):66-82. PubMed ID: 21193039
[TBL] [Abstract][Full Text] [Related]
5. Inhibitors of type II 17beta-hydroxysteroid dehydrogenase.
Poirier D; Bydal P; Tremblay MR; Sam KM; Luu-The V
Mol Cell Endocrinol; 2001 Jan; 171(1-2):119-28. PubMed ID: 11165020
[TBL] [Abstract][Full Text] [Related]
6. 17beta-Hydroxysteroid dehydrogenase inhibitors: a patent review.
Poirier D
Expert Opin Ther Pat; 2010 Sep; 20(9):1123-45. PubMed ID: 20645882
[TBL] [Abstract][Full Text] [Related]
7. Cinnamates and cinnamamides inhibit fungal 17beta-hydroxysteroid dehydrogenase.
Kristan K; Starcević S; Brunskole M; Rizner TL; Gobec S
Mol Cell Endocrinol; 2006 Mar; 248(1-2):239-41. PubMed ID: 16337334
[TBL] [Abstract][Full Text] [Related]
8. Design and validation of specific inhibitors of 17beta-hydroxysteroid dehydrogenases for therapeutic application in breast and prostate cancer, and in endometriosis.
Day JM; Tutill HJ; Purohit A; Reed MJ
Endocr Relat Cancer; 2008 Sep; 15(3):665-92. PubMed ID: 18541621
[TBL] [Abstract][Full Text] [Related]
9. Chemical synthesis of 16beta-propylaminoacyl derivatives of estradiol and their inhibitory potency on type 1 17beta-hydroxysteroid dehydrogenase and binding affinity on steroid receptors.
Tremblay MR; Lin SX; Poirier D
Steroids; 2001 Nov; 66(11):821-31. PubMed ID: 11576622
[TBL] [Abstract][Full Text] [Related]
10. Novel inhibitors of 17beta-hydroxysteroid dehydrogenase type 1: templates for design.
Allan GM; Vicker N; Lawrence HR; Tutill HJ; Day JM; Huchet M; Ferrandis E; Reed MJ; Purohit A; Potter BV
Bioorg Med Chem; 2008 Apr; 16(8):4438-56. PubMed ID: 18329273
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of type 1 17β-hydroxysteroid dehydrogenase impairs the synthesis of 17β-estradiol in endometriosis lesions.
Delvoux B; D'Hooghe T; Kyama C; Koskimies P; Hermans RJ; Dunselman GA; Romano A
J Clin Endocrinol Metab; 2014 Jan; 99(1):276-84. PubMed ID: 24187399
[TBL] [Abstract][Full Text] [Related]
12. 17beta-hydroxysteroid dehydrogenases in human breast cancer.
Nagasaki S; Miki Y; Akahira J; Suzuki T; Sasano H
Ann N Y Acad Sci; 2009 Feb; 1155():25-32. PubMed ID: 19250189
[TBL] [Abstract][Full Text] [Related]
13. Inhibitors of 17beta-hydroxysteroid dehydrogenase type 1.
Brozic P; Lanisnik Risner T; Gobec S
Curr Med Chem; 2008; 15(2):137-50. PubMed ID: 18220769
[TBL] [Abstract][Full Text] [Related]
14. Spironolactone-related inhibitors of type II 17beta-hydroxysteroid dehydrogenase: chemical synthesis, receptor binding affinities, and proliferative/antiproliferative activities.
Tremblay MR; Luu-The V; Leblanc G; Noël P; Breton E; Labrie F; Poirier D
Bioorg Med Chem; 1999 Jun; 7(6):1013-23. PubMed ID: 10428369
[TBL] [Abstract][Full Text] [Related]
15. Structure-function aspects and inhibitor design of type 5 17beta-hydroxysteroid dehydrogenase (AKR1C3).
Penning TM; Burczynski ME; Jez JM; Lin HK; Ma H; Moore M; Ratnam K; Palackal N
Mol Cell Endocrinol; 2001 Jan; 171(1-2):137-49. PubMed ID: 11165022
[TBL] [Abstract][Full Text] [Related]
16. Estrogen and androgen-converting enzymes 17β-hydroxysteroid dehydrogenase and their involvement in cancer: with a special focus on 17β-hydroxysteroid dehydrogenase type 1, 2, and breast cancer.
Hilborn E; Stål O; Jansson A
Oncotarget; 2017 May; 8(18):30552-30562. PubMed ID: 28430630
[TBL] [Abstract][Full Text] [Related]
17. Evolution of 17beta-hydroxysteroid dehydrogenases and their role in androgen, estrogen and retinoid action.
Baker ME
Mol Cell Endocrinol; 2001 Jan; 171(1-2):211-5. PubMed ID: 11165032
[TBL] [Abstract][Full Text] [Related]
18. A challenge for medicinal chemistry by the 17β-hydroxysteroid dehydrogenase superfamily: an integrated biological function and inhibition study.
Lin SX; Poirier D; Adamski J
Curr Top Med Chem; 2013; 13(10):1164-71. PubMed ID: 23647539
[TBL] [Abstract][Full Text] [Related]
19. Analysis and characteristics of multiple types of human 17beta-hydroxysteroid dehydrogenase.
Luu-The V
J Steroid Biochem Mol Biol; 2001; 76(1-5):143-51. PubMed ID: 11384872
[TBL] [Abstract][Full Text] [Related]
20. Development of hormone-dependent prostate cancer models for the evaluation of inhibitors of 17beta-hydroxysteroid dehydrogenase type 3.
Day JM; Tutill HJ; Foster PA; Bailey HV; Heaton WB; Sharland CM; Vicker N; Potter BV; Purohit A; Reed MJ
Mol Cell Endocrinol; 2009 Mar; 301(1-2):251-8. PubMed ID: 18786604
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
